Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion PhaseBusiness Wire · Oct 15, 2026
Estrella Immunopharma Activates Intermountain Health LDS Hospital as Fifth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's LymphomaBusiness Wire · Oct 14, 2026
Estrella Immunopharma (NASDAQ:ESLA) Trading Up 1.1% – Should You Buy?Defense World · Aug 21, 2026
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's LymphomaBusiness Wire · Aug 11, 2026
Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's LymphomaBusiness Wire · Aug 3, 2026
Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's LymphomaBusiness Wire · Jul 29, 2026Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$0.05 | -$0.05 | Beat |
| May 13, 2026 | -$0.08 | -$0.05 | Beat |
| Mar 18, 2026 | -$0.18 | -$0.14 | Beat |
| Nov 12, 2025 | -$0.19 | -$0.13 | Beat |
| Aug 11, 2025 | -$0.07 | -$0.15 | Miss |
| May 14, 2025 | -$0.11 | -$0.06 | Beat |